Study of the effects of plant composition on blood glucose in type 2 diabetic patients "

Investigating the Effects of a Herbal Mixture of tribulus terrestris, Silybum marianum ?Trigonella foenum-graecum and cinnamon zeylanicum on Blood Glucose in Type 2 Diabetes

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090811002330N2

Enrollment

Registered

2018-02-09

Start date

2016-12-01

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Endocrine, nutritional and metabolic diseases

Interventions

Intervention 1: Intervention group: Patients are asked to mix and take a tablespoon of herbal combination on a daily basis, twice before (before lunch and before dinner) with a glass of water and doug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Male and female type 2 diabetes

Exclusion criteria

Exclusion criteria: Patients who are at high risk for not controlling glucose with a fixed dose of drug are excluded from this study

Design outcomes

Primary

Measure	Time frame
TG. Timepoint: Beginning of study. A week after taking the medication. End of the first month of experiment. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Cholesterol. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;LDL. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;HDL. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;VLDL. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Fasting blood glucose. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Blood glucose two hours after food. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Glycosylated hemoglobin. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;ALT. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;AST. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters usi	—

Measure

Time frame

TG. Timepoint: Beginning of study. A week after taking the medication. End of the first month of experiment. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Cholesterol. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;LDL. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;HDL. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;VLDL. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Fasting blood glucose. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Blood glucose two hours after food. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;Glycosylated hemoglobin. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;ALT. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters using common kits in the market and Autoanalyser.;AST. Timepoint: Beginning of study. A week after taking the medication. End of the first. Method of measurement: Measurement of blood parameters usi

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Seyed Hadi Mousavi

Mashhad University of Medical Sciences

MousaviH@mums.ac.ir+98 51 3882 9267

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026